CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Murat Kalayoglu

Former CEO, Cartesian Therapeutics

Search every verified Murat Kalayoglu interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Murat Kalayoglu, former CEO of Cartesian Therapeutics, discussed the company's clinical development and manufacturing challenges in a June 2021 podcast interview. He noted that Cartesian had advanced three of its six autoimmune, oncology, and respiratory candidates through Phase I/II clinical trials, with two more nearing Phase I entry that year. Kalayoglu also described his background, including co-founding Topokine, which he led through late-stage clinicals before selling to Allergan, and his academic training in immunology from the University of Wisconsin–Madison, followed by a Harvard residency and an MIT Sloan MBA. In the interview, Kalayoglu addressed the difficulties of achieving consistency in cell therapy manufacturing, stating that variability between lots derived from different sources is a significant challenge and that it may be difficult to make such manufacturing as consistent as that for monoclonal antibodies. He also commented on regulatory guidance, saying it provides a useful starting point but that companies must apply their own judgment based on the specific product and purpose, rather than following guidance rigidly.

Recent appearances

  • The Cell As The Delivery Vehicle

    Dr. Murat Kalayoglu, CEO, Cartesian Therapeutics explains that Cartesian ensures that the cells it administers, and therefore the RNA therapeutics that is administers, meet all the specifications the company sets forth in advance. Part of those specifications ensures that there are a certain number of cells that are indeed capable of expressing the RNA into the relevant protein and at certain levels. He explains that they have solved the problem before ever infusing the RNA therapeutic directly into the body, and therefore, the class of therapies Cartesian develops are referred to as RNA cell…

    Watch on YouTube ↗

  • Maryland Stem Cell Research Fund | ISSCR 2022 Focus Session

    Accelerating Cures - Translating Stem Cell Discoveries into Therapies Organized by Maryland Stem Cell Research Fund (MSCRF)* In this Focus session, join leaders in the field from Maryland, USA to explore the latest breakthroughs and advances in stem cell disease modeling and tissue engineering approaches. Also learn the key considerations to commercialize your discoveries, including insights on manufacturing and progressing to clinical trials. The topics will cover cutting-edge discoveries in cardiovascular, neurological and retinal disease as well as cell therapies for skin, bone and soft-ti…

    Watch on YouTube ↗

  • Dr. Murat Kalayoglu, President & CEO, Cartesian Therapeutics: The Leader in RNA Cell Therapy

    So uh cartesian is a pioneer in rna cell therapy so we are a clinical stage biotechnology company based out of gaithersburg in ...

    Watch on YouTube ↗

  • Murat Kalayoglu, MD, PhD - Cartesian Therapeutics (EP.89)

    Cartesian Therapeutics President & Chief Executive Officer, Murat Kalayoglu, MD, PhD, Returns to BioTalk to provide an update since his last visit on their cell and gene therapies, as well as fundraising successes.

    Watch on YouTube ↗

  • RNA-Engineered Cell Therapy With Cartesian's Dr. Murat Kalayoglu

    Cartesian President & CEO Murat Kalayoglu, M.D., Ph.D. has led three of his company's six autoimmune, oncology, and respiratory candidates through Phase I/II clinical trials and two more of them are on the cusp of entering Phase I this year. With so many programs in and entering the clinic, he's a great choice for a conversation on GMP expectations for phase I first-in-human trials. Glean insight from Cartesian's experiences and learn about the company's novel approach to RNA-engineered cell therapies for oncology and beyond on this episode of The Business of Biotech. #businessofbiotech #biop…

    Watch on YouTube ↗

  • Cartesian Therapeutics – Pioneering mRNA-Engineered Cell Therapy

    Dr. Murat Kalayoglu, President and CEO at Cartesian Therapeutics discusses the company’s proprietary cell therapy platform called RNA Armory℠ that enables mRNA-engineering of any cell with any combination of therapies to target any tissue. Cartesian engineers mRNA into cells, making impermanent changes and making cells that have predictable lives within the body. The RNA Armory℠ has generated a robust pipeline of differentiated therapies for autoimmune, oncologic, and respiratory disorders, with three therapies currently in clinical trial. Descartes-08, the first CAR T-cell therapy for autoim…

    Watch on YouTube ↗

  • Dr. Murat Kalayoglu Discusses New Frontline Cell Therapy Treatment for Multiple Myeloma

    Sure yeah so this is an mrna engineered car t therapy for treatment of a patients with newly diagnosed multiple myeloma these ...

    Watch on YouTube ↗

  • Doing Business in the USA

    The Maryland Tech Council’s CEO, Marty Rosendale, hosts a weekly Zoom podcast and Q&A called "CapitalM ZoomCast Live". These 90-minute episodes are traditionally designed to give companies access to the Maryland Tech Council's extensive network and statewide resources to navigate through operational challenges and to ask questions. On September 16th, we partnered with Montgomery County Economic Development Corporation for an exciting episode, featuring an international audience on Doing Business in the USA. Moderator: Martin Rosendale CEO, Maryland Tech Council Panelists: Brad Stewart S…

    Watch on YouTube ↗

  • Dr. Murat Kalayoglu, MD, Ph.D., Cartesian Therapeutics (EP.43)

    Cartesian Therapeutics’ President & CEO Murat Kalayoglu, MD, Ph.D., guests on BioTalk from the BioHealth Capital Region Investor Conference to talk about developing novel cell and gene therapies, building his company in the region, and also being an investor.

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →